A multi-center, randomized, double-blind, parallel, active-controlled phase III clinical trial to evaluate the efficacy and safety of 'GLA5PR GLARS-NF1 Tab.' and 'Pregabalin' in peripheral neuropathic pain

Inclusion Criteria:

• both male and female who are over 19-year-old
• patient whose pain scale is 4~9
• patient who has pain of mononeuropathy

Exclusion Criteria:

• patient whose CCr is <60ml/min
• patient who has other pain which is not from mononeuropathy
• patient who is going to have an operation during this study
• patient who has abnormal ECG